ckd glp 1 GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease GLP-1 RAs, Other Agents, Underused

The number of people deemed obese based on a body mass index of 30 or more is due to double from 1 billion to 2 billion by 2030, and the costs worldwide to hit $3tn by the same date, it warned

CrossRef Eating behavior patterns in relation to obesity phenotypes and beige adipose tissue content with a focus on young women

Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis

This brief makes one central argument: the companies that define the formulation science, clinical evidence, and category positioning for GLP-1 consumers now will hold leadership for a decade

thanks to its anti-melanogenic, anti-oxidant, anti-aging, and depigmenting properties